Search Within

Gary Ulaner

Formats
  1. Journal Article (95)
  2. Meeting Abstract (39)
  3. Miscellaneous (5)
  4. Review (4)
  5. Editorial (2)
  6. Book Whole (1)
  7. Guidelines (1)
Groups
  1. Molecular Imaging and Therapy Service (147)
  2. Radiology, Department of (147)
  3. Department of Medicine (75)
  4. Solid Tumor Oncology Division (60)
  5. GSK Faculty (59)
  6. Epidemiology and Biostatistics (46)

More Groups

People
  1. David Hyman (22)
  2. Christopher Riedl (21)
  3. Maxine Jochelson (21)
  4. Jason Lewis (20)
  5. Maura Dickler (19)
  6. Komal Jhaveri (18)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (2)
  4. 2022 (2)
  5. 2021 (12)
  6. 2020 (21)

More Years

Publications
  1. Journal of Nuclear Medicine (24)
  2. Clinical Nuclear Medicine (23)
  3. Journal of Clinical Oncology (16)
  4. Cancer Research (8)
  5. PET Clinics (7)
  6. European Journal of Nuclear Medicine and Molecular Imaging (6)

More Publications

Publishers
  1. Lippincott Williams & Wilkins (27)
  2. Society of Nuclear Medicine (24)
  3. American Society of Clinical Oncology (16)
  4. Elsevier Inc. (16)
  5. American Association for Cancer Research (12)
  6. Springer (8)

More Publishers

Results (147)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diagnostic role of fluorodeoxyglucose PET in breast cancer: A history to current application
    Journal Article

    Chakraborty, D.; Basu, S.; Ulaner, G. A.; Alavi, A.; Kumar, R.
    PET Clinics (2018)

    Fulltext@MSK | Save
  • Mazabraud's syndrome mimicking metastases on FDG PET/CT in a patient with colon cancer
    Journal Article

    Mahajan, S.; Goel, R.; Riedl, C.; Ulaner, G. A.
    Clinical Nuclear Medicine (2018)

    Fulltext@MSK | Save
  • First-in-human human epidermal growth factor receptor 2-targeted imaging using (89)Zr-Pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer
    Journal Article

    Ulaner, G. A.; Lyashchenko, S. K.; Riedl, C.; Ruan, S.; Zanzonico, P. B.; Lake, D.; Jhaveri, K.; Zeglis, B.; Lewis, J. S.; O'Donoghue, J. A.
    Journal of Nuclear Medicine (2018)

    Fulltext@MSK | Save
  • Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis analysis of data from the histology-independent, phase 2, open-label VE-BASKET study
    Journal Article

    Diamond, E. L.; Subbiah, V.; Lockhart, A. C.; Blay, J. Y.; Puzanov, I.; Chau, I.; Raje, N. S.; Wolf, J.; Erinjeri, J. P.; Torrisi, J.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Long-half-life (89)Z-labeled radiotracers can guide percutaneous biopsy within the PET/CT suite without reinjection of radiotracer
    Journal Article

    Cornelis, F. H.; Durack, J. C.; Pandit-Taskar, N.; Ulaner, G. A.; Lewis, J. S.; Morris, M. J.; Solomon, S. B.
    Journal of Nuclear Medicine (2018)

    Fulltext@MSK | Save
  • Single-agent dabrafenib for BRAF(V600E)-mutated histiocytosis
    Journal Article

    Bhatia, A.; Ulaner, G.; Rampal, R.; Hyman, D. M.; Abdel-Wahab, O.; Durham, B. H.; Dogan, A.; Ozkaya, N.; Lacouture, M. E.; Hajdenberg, J.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Adalimumab-induced Epstein-Barr virus-related lymphoproliferative disorder on FDG PET/CT
    Journal Article

    Ward, J.; Noy, A.; Ulaner, G.; Riedl, C.
    Clinical Nuclear Medicine (2018)

    Fulltext@MSK | Save
  • HER kinase inhibition in patients with HER2-and HER3-mutant cancers
    Journal Article

    Hyman, D. M.; Piha-Paul, S. A.; Won, H.; Rodon, J.; Saura, C.; Shapiro, G. I.; Juric, D.; Quinn, D. I.; Moreno, V.; Doger, B.; more...
    Nature (2018)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase 2 trial of single-agent cobimetinib for adults with BRAF V600-mutant and wild-type histiocytic disorders
    Meeting Abstract

    Diamond, E. L.; Durham, B. H.; Dogan, A.; Hyman, D. M.; Rampal, R. K.; Ulaner, G.; Brody, L.; Abdel-Wahab, O.
    Blood (2017)

    Fulltext@MSK | Save